drug · small molecule
cisplatin
Phase 3updated 5mo agoby Privo Technologies Inc🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 7- drugPRV-2113 co-mentions · 3 sources
- drugcisplatin SR3 co-mentions · 3 sources
- drugiCIP3 co-mentions · 3 sources
- drugPRV-1313 co-mentions · 3 sources
- tagOncology2 co-mentions · 1 sources
- companyVirginia Commonwealth University1 co-mentions · 1 sources
- companyNational Cheng-Kung University Hospital1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and mesothelioma and 135 investigational indications.
all catalysts(1)
Trials studying cisplatin
- phase2Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
- phase2A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- phase3A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase3Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- phase3Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
News(3)
- Platinum-based chemotherapy in childhood causes mutations that age the liverPlatinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumorsstat · 26d ago
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 4mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that